Helsinn (Switzerland)

Recent papers from Helsinn (Switzerland)

1. A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancerSupportive Care in Cancer · 2026
2. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a studyThe Lancet · 2026
3. Beyond the score: a structured NPS-based analytical framework for explanatory insight and continuous improvementMeasuring Business Excellence · 2026
4. Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301ESMO Open · 2026
5. Abstract PS2-02-01: Improved Antiemetic Outcomes with NEPA vs (Fos)aprepitant in Patients with Breast Cancer Receiving Antibody-Drug Conjugates: A 12-Month Real-World Claims AnalysisClinical Cancer Research · 2026
6. Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trialSupportive Care in Cancer · 2026
7. The ghrelin receptor agonist AC01 improves cardiomyocyte contractility through Gαi signalling and without Ca2+ mobilizationCardiovascular Research · 2025
8. Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trialAnnals of Oncology · 2025
9. Anamorelin Efficacy in Non–Small‐Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2Journal of Cachexia Sarcopenia and Muscle · 2025
10. In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assaysEuropean Journal of Pharmacology · 2024
11. Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxisSupportive Care in Cancer · 2023
12. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsNature Cancer · 2023
13. IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune ToleranceCancer Research Communications · 2023
14. Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous FosnetupitantClinical Pharmacology in Drug Development · 2022
15. Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation TestingDermatology and Therapy · 2022
16. Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspectiveSupportive Care in Cancer · 2022
17. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsBlood Advances · 2021
18. Single-Dose Netupitant/Palonosetron Versus 3-day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled AnalysisFuture Oncology · 2021
19. Impact of Solvent and Their Contaminants on Pd/C Catalyzed Suzuki‐Miyaura Cross‐Coupling ReactionsHelvetica Chimica Acta · 2021
20. Implementing Historical Controls in Oncology TrialsThe Oncologist · 2021